Ambulatory Fluoroquinolone Use in the United States, 2015-2019.

ABSTRACT:

Background

Frequently used fluoroquinolones have been subject to increasing safety concerns and regulatory alerts. This study characterized ambulatory fluoroquinolone utilization in the United States and evaluated the impact of 2016 Food and Drug Administration (FDA) safety advisories on its use.

Methods

We used IQVIA's National Disease and Therapeutic Index to quantify adult outpatient fluoroquinolone use ("treatment visits"). Descriptive statistics and segmented regression were used to report trends and quantify the varied use before and after FDA's 2016 alerts.

Results

Between 2015 to 2019, fluoroquinolone use decreased by 26.7% (18.7 million treatment visits in 2015 to 13.7 million treatment visits in 2019). Annual use declined by 44%, 24%, and 24% for respiratory

SUBMITTER: Umarje SP 

PROVIDER: S-EPMC8659351 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature